A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

NCT06055985 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

OTHER: Placebo
DRUG: UCB0022

Sponsor

UCB Biopharma SRL